2024预见ASCO｜头颈肿瘤领域中国之声一览

前言

一年一度的肿瘤界“奥斯卡”——2024年美国临床肿瘤学会（ASCO）年会将于当地时间5月31日-6月4日在美国芝加哥盛大召开，众多国际重磅的临床科研成果将在ASCO大会期间披露。本文将聚焦头颈肿瘤领域，一起“预见”那些有望改变临床实践的中国之声！

Oral Abstract Session

摘要号：LBA6000

Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.

卡瑞利珠单抗辅助治疗高危局部晚期鼻咽癌(DIPPER)：一项多中心、开放标签、III期随机对照试验

讲者：刘需 中山大学肿瘤防治中心

摘要号：6001

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.

替雷利珠单抗对比安慰剂联合诱导化疗序贯同步放化疗，继以替雷利珠单抗或安慰剂辅助治疗局部晚期鼻咽癌：一项多中心、随机、安慰剂对照、双盲、III期试验的期中分析

讲者：陈秋燕 中山大学肿瘤防治中心

摘要号：6002

Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.

Endostar联合同步放化疗对比单纯同步放化疗应用于局部晚期咽癌(LA-NPC)的疗效：一项III期、前瞻性、随机对照、多中心临床试验

讲者：康敏 广西医科大学第一附属医院

Clinical Science Symposium

摘要号：6011

Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial.

信迪利单抗联合含铂双药化疗新辅助治疗经口机器人手术治疗的HPV相关可切除口咽癌：单臂II期试验

讲者：宋明 中山大学肿瘤防治中心

Rapid Oral Abstract Session

摘要号：6013

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.

pucotenlimab联合表皮生长因子受体-抗体药物偶联物(EGFR-ADC)MRG003治疗EGFR阳性实体肿瘤患者的I/II期研究初步结果

讲者：阮丹云 中山大学肿瘤防治中心

摘要号：LBA6018

Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial.

共价结合的FAPI PET可精准治疗髓样甲状腺癌：一项前瞻性单臂比较性临床试

讲者：孔梓任 中国医学科学院肿瘤医院

Poster Session

摘要号：6023

Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.

帕博利珠单抗联合白蛋白结合型紫杉醇和铂类药物作为复发性或转移性头颈鳞癌（R/M HNSCC）患者的一线治疗：一项前瞻性、单臂、开放标签的II期研究

讲者：桂琳 中国医学科学院肿瘤医院

摘要号：6024

Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.

在诱导化疗后尼妥珠单抗与同步放化疗联合治疗局部晚期鼻咽癌患者

讲者：吴三纲 厦门大学附属第一医院

摘要号：6026

Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).

DUBHE-N-302多中心、单臂、II期试验：iparomlimab和tuvonralimab与吉西他滨和顺铂联合作为复发性或转移性鼻咽癌患者一线治疗的疗效和安全性

讲者：黄岩 中山大学肿瘤防治中心

摘要号：6027

The role and mechanism of circadian clock gene BMAL1 in the proliferation and metastasis of nasopharyngeal carcinoma by inhibition TGF-β1/Smads pathway.

BMAL1基因在抑制TGF-β1/Smads通路中对鼻咽癌增殖和转移的作用和机制

讲者：赵朝芬 贵州医科大学附属医院

摘要号：6030

Identifying patients at high risk of recurrence by rebound of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma.

通过鼻咽癌患者血浆中Epstein-Barr病毒DNA的回升来识别高复发风险患者

讲者：Qixian Zhang 复旦大学附属肿瘤医院

摘要号：6033

Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.

抗LAG-3抗体LBL-007与抗PD-1抗体替雷利珠单抗联合应用，联合或不联合化疗，用于晚期鼻咽癌和其他恶性肿瘤患者的Ib/II期剂量递增/扩展研究

讲者：杨云鹏 中山大学肿瘤防治中心

摘要号：6039

Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).

特瑞普利单抗与安慰剂联合吉西他滨和顺铂作为复发性或转移性鼻咽癌（r/m NPC）一线治疗的四年总生存率随访结果和动态EBV滴度分析

讲者：陈秋燕 中山大学肿瘤防治中心

摘要号：6040

Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.

安罗替尼和派安普利单抗联合化疗在转移性鼻咽癌患者中的长期疗效：对于经典铂类化疗放疗失败的患者的治疗结果

讲者：黄爽 浙江省肿瘤医院

摘要号：6043

Associations of ctDNA clearance and pathological response after neoadjuvant treatment in patients with locally advanced oral cancer.

局部晚期口腔癌患者新辅助治疗后的ctDNA清除和病理反应的关联性

讲者：钟来平 复旦大学附属华山医院

摘要号：6044

An open-label, single-center phase II trial of cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma.

一项开放标签、单中心的II期试验：卡度尼利单抗（一种抗PD-1/CTLA-4双特异性抗体）与含铂双药新辅助化疗联合应用于局部晚期可切除头颈部鳞状细胞癌患者

讲者：Fei Cao 中山大学肿瘤防治中心

摘要号：6045

Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma.

与新辅助化疗和同步放化疗相比，替雷利珠单抗联合新辅助化疗和同步放化疗治疗局部晚期鼻咽癌的疗效

讲者：罗海清 广东医科大学附属医院

摘要号：6046

Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.

肌肉萎缩对既往经治复发转移性鼻咽癌患者的治疗反应和生存影响：来自KL-A167随机试验的二次分析的认识

讲者：刘哲然 四川大学华西医院

摘要号：6070

Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: A single-arm, phase II trial.

替雷利珠单抗联合新辅助化疗后进行挽救手术和辅助替雷利珠单抗治疗放疗后复发的头颈部鳞状细胞癌患者：一项单臂、II期试验

讲者：伍文杰 北京大学口腔医院

摘要号：6071

A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma.

一项前瞻性多中心试验：在局部晚期鼻咽癌患者中，顺铂和吉西他滨诱导化疗后，每周吉西他滨与调强放射治疗同时进行剂量递增的治疗

讲者：Zeng Qi 中山大学附属第五医院

摘要号：6072

Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.

高危N2-3鼻咽癌患者诱导-同步对比同步-辅助放化疗：一项开放标签、随机对照的III期试验

讲者：陈秋燕 中山大学肿瘤防治中心

摘要号：6073

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.

新辅助替雷利珠单抗联合阿法替尼治疗局部晚期头颈部鳞状细胞癌（neoCHANCE-1）：一项开放标签、单臂、II期研究

讲者：卫治功 四川大学华西医院

摘要号：6074

Analysis of PD-L1 expression in locally advanced head and neck squamous cell carcinoma and its correlation with the efficacy of neoadjuvant immunotherapy + chemotherapy: A retrospective real-world study.

局部晚期头颈部鳞状细胞癌中PD-L1表达的分析及其与新辅助免疫治疗+化疗疗效的相关性：一项回顾性真实世界研究

讲者：谭浩蕾 中南大学湘雅医学院附属肿瘤医院

摘要号：6075

Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.

顺序放化疗对比诱导化疗加同步放化疗治疗区域局部晚期鼻咽癌的多中心、开放标签、非劣效性、随机、III期试验

讲者：胡超苏 复旦大学附属肿瘤医院

摘要号：6078

Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

新辅助免疫化疗治疗局部晚期下咽鳞状细胞癌：来自两个前瞻性单臂II期试验的汇总结果分析

讲者：桂琳 中国医学科学院肿瘤医院

摘要号：6080

Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.

纳武利尤单抗与放化疗（避免同时使用顺铂）联合治疗高危局部区域晚期鼻咽癌（PLATINUM）：一项由研究者发起的、开放标签、多中心、单臂、II期临床试验

讲者：Cheng Xu 中山大学肿瘤防治中心

摘要号：6084

Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.

特瑞普利单抗新辅助和辅助治疗高危局部晚期鼻咽癌：一项随机、双盲、安慰剂对照的II期临床试验

讲者：刘赛兰 中山大学肿瘤防治中心

摘要号：6085

MR radiomics and neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.

MR放射组学和新辅助化疗反应性，对HPV阳性口咽癌中选择性治疗降低强度的认识

讲者：Xueguan Lu

摘要号：6086

Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.

诱导化疗后同步放化疗联合特瑞普利单抗和恩度治疗高危局部晚期鼻咽癌患者：一项多中心、随机、II期临床试验

讲者：康敏 广西医科大学第一附属医院

摘要号：6090

Neoadjuvant immunochemotherapy and new radiomic predictor for resectable locally advanced oral squamous cell carcinoma.

可切除局部晚期口腔鳞状细胞癌的新辅助免疫化疗和放射组学预测因子

讲者：刘磊 四川大学华西医院

摘要号：6094

Clinical and genomic characterization of sporadic medullary thyroid carcinoma in Chinese patients.

中国患者散发性髓样甲状腺癌的临床和基因组特征描述

讲者：Yang Liu

摘要号：6099

Survival outcomes of concurrent radiotherapy and toripalimab versus radiotherapy alone for elderly patients with postoperative head and neck squamous cell carcinoma unfit for cisplatin.

不适合使用顺铂的老年头颈部鳞状细胞癌术后患者，接受同步放疗联合特瑞普利单抗与仅放疗的生存结果

讲者：窦圣金 上海交通大学附属第九人民医院

摘要号：6103

Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma.

安罗替尼联合信迪利单抗治疗局部晚期或转移性间变性甲状腺癌的疗效和安全性

讲者：Haohua Zhu 中国医学科学院肿瘤医院

摘要号：6105

The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.

ulinastatin在预防和治疗放疗引起的局部区域晚期鼻咽癌（LA-NPC）口腔黏膜炎的疗效和安全性：一项多中心、开放标签、随机对照临床试验

讲者：王琳 中山大学肿瘤防治中心

摘要号：6108

Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study.

吡咯替尼在HER2突变的晚期唾液腺癌中的应用：来自一项探索性研究的两个队列的分析

讲者：窦圣金 上海交通大学附属第九人民医院

摘要号：6110

A non-invasive cfDNA fragmentomics assay for differentiating malignant and benign thyroid nodules.

一种非侵入性的循环游离DNA片段组学检测方法，用于区分恶性和良性甲状腺结节

讲者：单臻 中山大学第一附属医院

摘要号：TPS6123

EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.

III期EFFECT-neo研究：帕博利珠单抗联合化疗对比化疗作为可切除局部晚期头颈部鳞状细胞癌的新辅助治疗的疗效

讲者：张洋 北京同仁医院

摘要号：TPS6129

Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.

阿得贝利单抗联合达尔西利新辅助治疗非HPV相关局部晚期头颈部鳞状细胞癌：一项II期临床试验

讲者：刘磊 四川大学华西医院

编辑：Faline

审校：Faline

排版：KIKI

执行：Uni

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。